Klasifikasi dan Diagnosis Anemia dan Leukemia
Diunggah oleh
RONA SALSABILLA SEPTIWIYANTIKlasifikasi dan Diagnosis Anemia dan Leukemia
Diunggah oleh
RONA SALSABILLA SEPTIWIYANTICommon questions
Didukung oleh AIMacrocytic anemia is characterized by an elevated mean corpuscular volume (MCV), commonly due to defective DNA synthesis, most notably in conditions like vitamin B12 or folate deficiency . In pernicious anemia, a common form of macrocytic anemia, autoantibodies to intrinsic factor prevent B12 absorption, leading to megaloblastic hematopoiesis . Hemolytic anemia with elevated corpuscular destruction can also be macrocytic if bone marrow responds by overproducing reticulocytes, which are larger than average red cells . Determining if the anemia is megaloblastic, related to vitamin deficiencies, or otherwise requires checking serum B12, folate, and possibly homocysteine/methylmalonic acid levels.
Hepatosplenomegaly, the enlargement of liver and spleen, is a common finding in several hematological malignancies due to various pathophysiological processes. In conditions like chronic myelogenous leukemia (CML), the spleen often enlarges as it clears excessive granulocytes resulting from the high proliferative activity of myeloid cells . In contrast, myeloproliferative disorders like chronic lymphocytic leukemia (CLL) cause spleen and liver enlargement due to infiltration by lymphocytes and immune complexes . In the context of myelodysplastic syndromes, chronic inflammation and extramedullary hematopoiesis lead to organ enlargement . These differences help delineate disease mechanisms, where hepatosplenomegaly indicates not only disease presence but also the subtype and progression stage.
CLL presents with a persistent high lymphocyte count that typically includes mature small lymphocytes with condensed chromatin. Smudge cells, indicative of fragile leukocytes, are a characteristic finding on peripheral blood smear . Immunophenotyping typically reveals a CD5+ B-cell lineage, and monoclonal B-cell expansion confirms the diagnosis . Clinically, patients may exhibit lymphadenopathy, splenomegaly, and immunodeficiency symptoms due to dysfunctional lymphocytes. The slow progression and absence of anemia or thrombocytopenia in early stages help distinguish CLL from other leukemias.
Reticulocyte count indicates the bone marrow's response to anemia. In conditions of increased red blood cell destruction or loss, such as hemolytic anemias, the reticulocyte count is typically elevated as the marrow compensates for increased loss . Conversely, in iron deficiency anemia or aplastic anemia, where production is impaired, the reticulocyte count is low due to insufficient erythropoiesis . Thus, a high reticulocyte count suggests a compensatory response, while a low count suggests a production failure, aiding differentiation between destructive and hypoproliferative anemias.
Chronic myelogenous leukemia (CML) is characterized by extreme leukocytosis with mature and immature granulocytes across the spectrum, including presence of myeloblasts and the hallmark Philadelphia chromosome . It typically presents with splenomegaly and symptoms related to high white cell turnover. In contrast, chronic lymphocytic leukemia (CLL) is identified by a high count of mature lymphocytes and smudge cells in peripheral blood, with immunophenotyping confirming monoclonal B-cell expansion . CLL often presents with lymphadenopathy and symptoms related to immune dysfunction due to ineffective lymphocytes. The two are differentiated by the dominant cell type and cytogenetic markers.
Auer rods are cytoplasmic inclusions found in myeloblasts, composed of fused lysosomal granules, and their presence is diagnostic of AML . They indicate a higher degree of myeloid differentiation and are associated with certain subtypes of AML such as acute promyelocytic leukemia (APL), which often requires targeted treatment with all-trans retinoic acid (ATRA) and arsenic trioxide . The presence of Auer rods in blasts signals a risk for disseminated intravascular coagulation (DIC) due to release of pro-coagulant granules during blast turnover, necessitating careful coagulation monitoring and supportive care in affected patients. This inclusion signifies a specific leukemic morphology that guides therapeutic approaches and prognostication.
ALL and AML diagnosis primarily differ based on the type of progenitor cell involved; ALL involves lymphoid progenitors, while AML involves myeloid progenitors. Morphologically, ALL is confirmed by identifying >20% lymphoblasts in blood or bone marrow, with specific immunophenotyping indicating B- or T-lineage . AML is diagnosed with the presence of myeloblasts exhibiting Auer rods in cytoplasm, supported by myeloid marker expression in immunophenotyping . Management diverges at chemotherapy regimens and potential hematopoietic stem cell transplantation. ALL typically responds to vincristine, corticosteroids, and asparaginase, while AML treatment involves cytarabine and anthracyclines . Treatment success and complications significantly differ, particularly due to marrow dysplasia in AML, requiring rigorous supportive care.
AIHA is an immune-mediated condition where antibodies target red blood cells for destruction, leading to normocytic or normochromic anemia with positive direct Coombs test . Thalassemia results from genetic defects affecting globin chain synthesis, causing ineffective erythropoiesis and iron overload. Lab findings in AIHA include increased reticulocyte count and indirect hyperbilirubinemia, while thalassemia presents with microcytic, hypochromic cells, target cells, and elevated serum ferritin or transferrin . AIHA is driven by autoimmune processes, while thalassemia stems from inherited genetic abnormalities, distinctly illustrated by their differing laboratory profiles.
Multiple myeloma is primarily diagnosed via clinical presentation and specific laboratory findings. The presence of monoclonal protein in the serum or urine is key, identified through serum protein electrophoresis and immunofixation electrophoresis . Serum free light chain assay can detect light chain disease. Bone marrow biopsy revealing >10% clonal plasma cells confirms diagnosis . Skeletal surveys or MRI may reveal lytic bone lesions, and the combination of hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB criteria) guides diagnosis . These tests, in conjunction, are critical for comprehensive disease assessment.
Iron deficiency anemia is characterized by low hemoglobin, MCV, and MCH levels, reflecting the decreased availability of iron for hemoglobin synthesis. Fe storage and serum iron levels are also reduced, while TIBC may be normal or increased due to the body's attempt to compensate for low iron . Thalassemia, in contrast, involves abnormal hemoglobin production due to defects in globin chain synthesis, leading to low MCV and MCH but with increased RBC count and reticulocytosis, as the body attempts to compensate for ineffective erythropoiesis . These differences reflect the underlying pathophysiological mechanisms: iron deficiency affects iron metabolism directly, while thalassemia affects globin chain production.